Analysts Not Impressed With GlaxoSmithKline plc (ADR) (NYSE:GSK) And CEO Andrew Witty
Analysts are hoping that GlaxoSmithKline plc (ADR) (NYSE:GSK) can stabilize the company amid a series of new strategies that the CEO, Andrew Witty, has been […]
Analysts are hoping that GlaxoSmithKline plc (ADR) (NYSE:GSK) can stabilize the company amid a series of new strategies that the CEO, Andrew Witty, has been […]